BILLERICA, Mass., Feb. 27, 2012 /PRNewswire/ -- EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced it will be partnering with Charles River Laboratories International, Inc. of Wilmington, MA, to exclusively license EMD Millipore's TrueSpike™ technology. EMD Millipore and Charles River will collaborate to integrate the TrueSpike™ technology into viral clearance services provided by Charles River, which is designed to result in a more predictable and consistent study outcome for clients, and ultimately helping to improve drug product safety. The combined expertise of these two industry leaders will result in higher purity virus preparations to help ensure validation success and regulatory compliance for biopharmaceutical manufacturers.
"This exclusive partnership with Charles River brings together their regulatory and viral clearance experience and our extensive knowledge of virus filtration and process engineering," describes Christophe Couturier, Vice President of Services and Solutions, EMD Millipore. "The increased quality of virus preparations as delivered by TrueSpike™ technology will help ensure the success of our customers' validation studies conducted by Charles River."
TrueSpike™ technology enables removal of cell debris, DNA, and non-viral proteins from virus preparations used to validate biomanufacturing process virus clearance. Use of TrueSpike™ technology reduces the protein content of virus preparations used for validation studies up to 600 fold, as demonstrated with our TrueSpike MVM (minute mouse virus). A significantly cleaner prep can lead to increased predictability of validation studies, enabling assured achievement of validation targets.
"Our goal at Charles River is to
|SOURCE EMD Millipore|
Copyright©2010 PR Newswire.
All rights reserved